Red X iconGreen tick iconYellow tick icon

Christopher FramptonProfessor

BSc(Hons) PhD(Cant)

Chris Frampton is the departmental biostatistician and is involved in departmental teaching and the design and analysis of research studies.

His particular research interests include the modelling and prediction of long-term outcome data, and developing structural equation models for defining personality constructs.

Publications

Lingard, M. C. H., Teo, Y., Frampton, C. M. A., & Hooper, G. J. (2023). Effect of surgeon-specific feedback on surgical outcomes: A systematic review of the literature. ANZ Journal of Surgery. Advance online publication. doi: 10.1111/ans.18772

Prendergast, E., Dalbeth, N., Bursill, D., Frampton, C., & Stamp, L. (2023). Adherence to the Gout and Crystal Arthritis Network (G-CAN) consensus statements for gout nomenclature. Arthritis & Rheumatology, 75(Suppl. 9), 0238. doi: 10.1002/art.42700

Tennant, M., Frampton, C., Mulder, R., & Beaglehole, B. (2023). Polypharmacy in the treatment of people diagnosed with borderline personality disorder: Repeated cross-sectional study using New Zealand's national databases. BJPsych Open, 9(6), e200. doi: 10.1192/bjo.2023.592

Prendergast, E., Dalbeth, N., Bursill, D., Frampton, C., & Stamp, L. K. (2023). Uptake of the Gout and Crystal Arthritis Network (G-CAN) consensus statements for gout nomenclature. Arthritis Care & Research. Advance online publication. doi: 10.1002/acr.25250

Stamp, L., Horne, A., Mihov, B., Drake, J., Haslett, J., Chapman, P. T., Frampton, C., & Dalbeth, N. (2023). Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Annals of the Rheumatic Diseases, 82, 1626-1634. doi: 10.1136/ard-2023-224731

Back to top